September Drug Summary

In September, the FDA cleared Genentech’s Gavreto for patients with genetically altered lung cancer and approved Bristol Myers Squibb’s Onureg for acute myeloid leukemia. Qdolo permits greater tramadol dosing flexibility for pain, and new Trulicity doses may improve A1C and weight. Trelegy Ellipta is OK’d for asthma maintenance, and Xeljanz grabs its first pediatric indication. Nucala is the first biologic for hypereosinophilic syndrome, and Haegarda use for hereditary angioedema prevention is expanded for even younger patients.


Recent Posts

See All

Admin Login by RSP

Admin Login by Center Team

Dear Visitors !

Articles written by authors are their views and their presentation of ideas and knowledge. CHEARS does not claim right on write-up and authors are the real owner and are responsible for their write-up or views. Posts from CHEARS News Room are interpretations or presentation of news from various news resources. 

Posts from executive committee members are posts from CHEARS Office.  

© Copyright CHEARS

© Center for Health Education, Awareness Resources and Services

Subscribe to Our Newsletter